References
- Amador-Molina A, Hernandez-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M (2013). Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses, 5, 2624-42. https://doi.org/10.3390/v5112624
- Bais AG, Beckmann I, Ewing PC, et al (2007). Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm, 2007, 24147.
- Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V (2008). Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest, 26, 1037-43. https://doi.org/10.1080/07357900802112693
- Boccardo E, Lepique AP, Villa LL (2010). The role of inflammation in HPV carcinogenesis. Carcinogenesis, 31, 1905-12. https://doi.org/10.1093/carcin/bgq176
- Chumworathayi B, Thinkhamrop J, Blumenthal PD, et al (2010). Cryotherapy for HPV clearance in women with biopsyconfirmed cervical low-grade squamous intraepithelial lesions. Int J Gynaecol Obstet, 108, 119-22. https://doi.org/10.1016/j.ijgo.2009.09.012
- Clerici M, Ferrario E, Trabattoni D, et al (1997). Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst, 89, 245-50. https://doi.org/10.1093/jnci/89.3.245
- Dwivedi S, Goel A, Natu SM, et al (2011). Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8.
- El-Sherif AM, Seth R, Tighe PJ, Jenkins D (2001). Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol, 195, 179-85. https://doi.org/10.1002/path.929
- Jacob M, Broekhuizen F, Castro W, Sellors J (2005). Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet, 89, 13-20. https://doi.org/10.1016/j.ijgo.2005.01.026
- Jaisamrarn U, Castellsague X, Garland SM, et al (2013). Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One, 8, 79260. https://doi.org/10.1371/journal.pone.0079260
- Kim HJ, Kim SY, Lim SJ, et al (2010). One-step chromatographic purification of human papillomavirus type 16 L1 protein from< i> Saccharomyces cerevisiae. Protein Express Purif, 70, 68-74. https://doi.org/10.1016/j.pep.2009.08.005
- Koshiol J, Lindsay L, Pimenta JM, et al (2008). Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 168, 123-37. https://doi.org/10.1093/aje/kwn036
- Marais DJ, Constant D, Allan B, et al (2008). Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J Clin Microbiol, 46, 732-9. https://doi.org/10.1128/JCM.01322-07
- Mohanty K, Lowe J (1990). Cryotherapy in the management of histologically diagnosed subclinical human papilloma virus (HPV) infection of the cervix. Brit J Clin Pract, 44, 574-7.
- Moore MA, Tajima K (2004). Cervical cancer in the asian pacific-epidemiology, screening and treatment. Asian Pac J Cancer Prev, 5, 349-61.
- Onda T, Carter JJ, Koutsky LA, et al (2003). Characterization of IgA response among women with incident HPV 16 infection. Virology, 312, 213-21. https://doi.org/10.1016/S0042-6822(03)00196-X
- Passmore J, Morroni C, Shapiro S, Williamson A-L, Hoffman M (2007). Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm, 4, 8. https://doi.org/10.1186/1476-9255-4-8
- Poomtavorn Y, Suwannarurk K, Thaweekul Y, Maireang K (2009). Cervical cytologic abnormalities of cervical intraepithelial neoplasia 1 treated with cryotherapy and expectant management during the first year follow-up period. Asian Pac J Cancer Prev, 10, 665-8.
- Saxena U, Sauvaget C, Sankaranarayanan R (2012). Evidencebased screening, early diagnosis and treatment strategy of cervical cancer for national policy in low- resource countries: example of India. Asian Pac J Cancer Prev, 13, 1699-703. https://doi.org/10.7314/APJCP.2012.13.4.1699
- Song SH, Lee JK, Lee NW, et al (2008). Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol, 108, 543-8. https://doi.org/10.1016/j.ygyno.2007.11.006
- Spellberg B, Edwards JE (2001). Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis, 32, 76-102. https://doi.org/10.1086/317537
- Stanley M (2008). Immunobiology of HPV and HPV vaccines. Gynecol Oncol, 109, 15-21. https://doi.org/10.1016/j.ygyno.2008.02.003
- Tjiong MY, van der Vange N, ter Schegget JS, et al (2001). Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine, 14, 357-60. https://doi.org/10.1006/cyto.2001.0909
- Winer RL, Hughes JP, Feng Q, et al (2011). Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev, 20, 699-707. https://doi.org/10.1158/1055-9965.EPI-10-1108
- Zhao YH, Wang T, Yu GF, et al (2013). Anti-proliferation effects of interferon-gamma on gastric cancer cells. Asian Pac J Cancer Prev, 14, 5513-8. https://doi.org/10.7314/APJCP.2013.14.9.5513
Cited by
- Transformation of the genital epithelial tract occurs early in California sea lion development vol.3, pp.3, 2016, https://doi.org/10.1098/rsos.150419